Simba Gill sold $57 of EVLO
President & CEO at Evelo Biosciences, Inc.. 172 shares at an average of $0.33, traded Nov 8, 2023, filed Nov 8, 2023.
Score components
- +25RoleCEO
- 0Trade size$57 at market
- 0Share of holdings soldSold 1.0% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001694665-23-000176, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2023 | MOption exercise Common Stock10b5-1 | +1,172 | - | - | 17,930 | Nov 8, 2023 |
| Nov 8, 2023 | SOpen-market sale Common Stock10b5-1 | -172 | $0.33 | $57 | 17,758 | Nov 8, 2023 |
| Nov 7, 2023 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -1,172 | $0.00 | $0 | 15,236 | Nov 8, 2023 |
Related signals
Other insiders at Evelo Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 5Weak | Evelo Biosciences, Inc. | Mark Bodmer CSO, President of R&D | $1,044 3,163 shares | -11% | |
| 2Weak | Evelo Biosciences, Inc. | Marella Thorell Chief Financial Officer | $598 1,811 shares | -8% | |
| 0Weak | Evelo Biosciences, Inc. | Duncan McHale Chief Medical Officer | $1,024 3,103 shares | -15% | |
| 5Weak | Evelo Biosciences, Inc. | Mark Bodmer CSO, President of R&D | $2,262 6,854 shares | -24% | |
| 7Weak | Evelo Biosciences, Inc. | Marella Thorell Chief Financial Officer | $1,320 3,999 shares | -19% | |
| 5Weak | Evelo Biosciences, Inc. | Duncan McHale Chief Medical Officer | $2,262 6,854 shares | -34% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.